Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...

While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentiated mechanism and broader label.

University of Pittsburgh Medical School researchers walk us through multiple approaches they’ve tried in the past, are currently using or plan to use in the future, as well as the significant ...

Frontier Group (ULCC) disclosed last night that it expects revenue growth in Q1 of 5% on capacity growth of 5%, both compared to the corresponding prior year quarter.Revenue growth is anticipated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...